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Abstract
Background: Positive blood cultures showing Gram positive cocci in clusters signifies either Staphylococcus aureus or the
less-virulent coagulase-negative staphylococci. Rapid identification and methicillin susceptibility determination with the Xpert
MRSA/SA BC assay can improve management of S. aureus bloodstream infection and reduce inappropriate antibiotic use.
Methods: We prospectively evaluated the Xpert MRSA/SA BC assay in comparison with culture, on samples referred to our
laboratory in the Western Cape, South Africa. We interviewed attending clinicians upon culture result availability, to assess
antibiotic choices and estimate potential impact of the assay.
Results: Of the 231 samples included, there was 100% concordance between the Xpert MRSA/SA BC assay and culture
(methicillin-resistant S. aureus 15/15, methicillin-susceptible S. aureus 42/42, coagulase-negative staphylococci 170/170). Time to
final result could be reduced by approximately 30 h with the assay. Of the 178 patients with adequate antibiotic history,
optimisation of antistaphylococcal therapy could have occurred more than 1 day sooner in 68.9% with S. aureus bloodstream
infection (31/45, 95% CI 53.2–81.4%). Six of the 11 patients with methicillin-resistant S. aureus bloodstream infection (54.5%)
could have received anti-MRSA cover sooner. Fifty-four days of antibiotic therapy could have been spared, equating to 0.3 days
(95% CI, 0.2–0.4) saved per patient, driven by broad-spectrum beta-lactams (32 days, in 18.0% of the cohort).
Conclusion: This assay has potential as an antimicrobial stewardship tool; costing and impact on clinical outcome in patients
with S. aureus bloodstream infection should be assessed.
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Background
Staphylococcus aureus is a common cause of blood-
stream infection (BSI) [1], with a mortality rate of 20–
40% [1]. In contrast, coagulase-negative staphylococci
(CoNS) are generally regarded as skin commensals of
low pathogenic potential, although they can be clinically
significant in selected circumstances.
Differentiating between CoNS and S. aureus in positive
blood culture broths showing Gram positive cocci in
clusters (GPCC) on Gram stain, typically requires assess-
ment of morphological and biochemical characteristics
after overnight incubation. In addition, susceptibility
testing is required to differentiate between methicillin-
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susceptible and methicillin-resistant S. aureus (MSSA
and MRSA, respectively). These requirements can result
in delayed initiation of appropriate therapy in patients
with S. aureus BSI, with potentially adverse outcomes in-
cluding secondary infectious complications [2], a higher
mortality rate and prolonged hospital stay [1]. Con-
versely, inappropriate antibiotic administration unneces-
sarily exposes the patient to potential adverse effects of
the medication, alters gastrointestinal flora, and also has
ecological effects, including contributing to antibiotic se-
lective pressure which drives resistance.
The Xpert MRSA/SA BC System (Cepheid, Sunnyvale,
California) differentiates between MRSA, MSSA and
CoNS from positive blood cultures within approximately
1 h, using a real-time, semi-automated, nucleic acid-based
test which targets spa and the SCCmec-orfX junction (for
S. aureus), and mecA (for methicillin resistance). Published
studies, summarised in one paper [3], report sensitivities
and specificities of 96.4–100% and 98.0–100% respectively,
for the detection of MSSA, and values of 87.5–100% and
98.3–100% respectively, for detection of MRSA. Initial
concerns regarding undercalling of MRSA with specific
SCCmec variants, were resolved in 2013 [3].
We evaluated the Xpert MRSA/SA BC System (Xpert)
and assessed the potential impact of implementation of this
test as an antimicrobial stewardship tool in the patient popu-
lation served by our laboratory in Cape Town, South Africa.
Methods
Study aims, design and setting
We aimed to assess the performance and role of the
Xpert in facilitating more appropriate antibiotic use in
patients with S. aureus bloodstream infection, and redu-
cing inappropriate antibiotic therapy in those with S.
aureus and with coagulase-negative staphylococci. We
performed a prospective observational study to evaluate
the Xpert against the reference method of culture-based
techniques, and to describe the potential impact of im-
plementation of this assay in our setting by combining
clinical history with attending clinician survey.
The study took place from January to June 2016 at the Na-
tional Health Laboratory Service (NHLS) Microbiology la-
boratory at Tygerberg Hospital in the Western Cape, South
Africa. Tygerberg Hospital is a 1384-bedded referral hospital
serving the northern and eastern subdistricts of the Cape
Metro region, and the surrounding rural districts, including
4 regional hospitals and 17 district hospitals.
Blood culture bottles were submitted from facilities
throughout this drainage area at the clinicians’ discre-
tion. The automated blood culture system in use is the
BacT/Alert 3D Microbial Detection System (bioMérieux,
Marcy L’Étoile, France) which includes anaerobic (FN
Plus), aerobic (FA Plus) and paediatric bottles (PF Plus).
These were kept at room temperature during transport,
and were incubated as soon as possible after specimen
receipt. After flagging positive, Gram stains are per-
formed on an aliquot of the broth. All patients with
positive blood cultures exclusively showing GPCC on
Gram stain, were included. Blood culture specimens
showing mixed morphology on Gram stain, and dupli-
cate blood culture samples from the same patient, were
excluded.
Paediatric patients were defined as patients below the
age of 13 years.
Classification and management of suspected sepsis
Patients with positive blood cultures (indicating sus-
pected sepsis) were defined as having community-
acquired (CA) infection if the culture was collected < 72
h after admission, and hospital acquired (HA) infection
thereafter; admission within the preceding 6 weeks
was also considered a criterion for HA infection [4] .
Empiric management of CA infections was based on
local guidelines, with ceftriaxone or amoxicillin-
clavulanate used for most infections; cloxacillin was rec-
ommended where S. aureus was likely. During the study
period, standard-of-care was to administer a carbapenem
+/− vancomycin (for suspected MRSA) for presumed
hospital-acquired sepsis.
Regional hospital guidelines in our drainage area ad-
vise a targeted approach of a semi-synthetic beta-
lactamase stable penicillin (cloxacillin) for MSSA BSI,
with vancomycin advised for MRSA BSI.
Validation
Laboratory processing
Consecutive samples were processed in parallel using
culture-based methods and Xpert, during weekdays be-
tween 8 am and 4 pm. The investigator performing the
Xpert was blinded to the culture results.
Culture-based methods entailed inoculation and over-
night incubation of basic enriched agar media; Kirby-
Bauer disk diffusion testing of an aliquot of broth against
a standard anti-staphylococcal antibiotic panel; and identi-
fication using DNAse and Mannitol Salt Agar (MSA)
plates. A rapid latex agglutination test was performed
using the Pastorex Staph Plus kit (Bio-Rad, Hercules, Cali-
fornia) for indeterminate identification results. VITEK 2
Gram positive ID confirmation (bioMérieux, Marcy
L’Étoile, France) was used at the discretion of the clinical
microbiologist, and methicillin susceptibility was deter-
mined by cefoxitin disk diffusion testing using the Clinical
and Laboratory Standards Institute (CLSI) guidelines [5].
Batched Xpert testing was performed on blood culture
bottles, which were stored at 35 °C following culture-
based processing. The Xpert MRSA/SA BC G3 version 5
(Cepheid, Sunnyvale, California) was performed as per
manufacturer’s instructions. Briefly, 50 μl of blood
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culture broth was added to the vial containing the elu-
tion reagent and vortexed for 10 s. The contents of the
vial were transferred to the test cartridge and loaded into
the module. Xpert testing was performed as soon as pos-
sible after positivity; there was a maximum delay of 80 h
for bottles flagging positive over a weekend. The results of
the Xpert assay were not made available to the clinicians.
The results of these methods were interpreted as sum-
marised in Table 1.
Impact assessment and definitions
As per standard practice, clinicians were contacted with
the Gram stain result if the available clinical information
or previous results suggested S. aureus sepsis, or if the
patient was admitted in an Intensive Care Unit (ICU). In
all other cases, clinicians were contacted with the culture
result, whether S. aureus or CoNS.
Basic clinical and demographic information were obtained,
including an antibiotic history. We surveyed the attending cli-
nicians to assess whether knowledge of the culture and sus-
ceptibility result on the day the bottle flagged positive would
have impacted antibiotic choice. This was categorised as:
 Modification: a change from an ineffective to a more
effective agent, or the addition of a semisynthetic
penicillin (MSSA) or glycopeptide (MRSA);
 De-escalation: a change in antibiotic to a narrower-
spectrum, targeted antistaphylococcal agent, or ces-
sation of some or all antibiotics;
 No change: no change to the empiric antibiotic
regimen, or no antibiotics prescribed if the patient
was not receiving antibiotics.
We regarded cephalosporins (with the exception of
ceftazidime), beta-lactam–beta-lactamase inhibitors, car-
bapenems and vancomycin as being active against
MSSA. Penicillin, ampicillin, amoxicillin, and ceftazidime
were the beta-lactam agents regarded as being ineffective
against MSSA.
CoNS were considered significant only if reported as
the likely cause for the patient’s clinical condition, as
judged by the attending clinician.
Days of antibiotic therapy saved were also evaluated
during clinician interview, based on the empiric antibiotic
regimen commenced and on clinician opinion as to
whether an earlier result would have impacted antibiotic
choice or duration (i.e. if the Xpert had been utilised as
soon as the bottle flagged positive, leading to a “final” re-
sult being available shortly after Gram stain availability).
Statistical analysis
Microsoft Excel, VassarStats (www.vassarstats.net) and
EpiCalc 2000 v1.02 (Brixton Books, South London, UK)
were used, with an α-level of 0.05 chosen. Continuous nu-
merical variables were summarised using means and
standard deviations for normally distributed variables, or
medians and interquartile ranges (IQR) for variables not
following a normal distribution. Binary categorical vari-
ables were summarised using proportions and 95% confi-
dence intervals (CI). Comparison of selected independent
proportions were evaluated using the z-test.
Results
Our laboratory processed 2822 positive blood culture bottles
between January and June 2016. Of these, 1158 (41.0, 95% CI
39.2–42.9%) demonstrated only GPCC on Gram stain and
Table 1 Laboratory processing result interpretation of positive blood cultures containing Gram positive cocci in clusters
Culture-based methods Xpert MRSA/SA BC
Species identification Methicillin susceptibility
determination
Species identification Methicillin susceptibility
determination
Methicillin-resistant
Staphylococcus aureus
DNAse and MSA positive;
OR DNAse and MSA
discrepanta AND S. aureus
on VITEK 2
Cefoxitin resistant on
disk diffusion testingb
Detection of
spa gene
Detection of mecA and
the SCCmec-orfX region
Methicillin-susceptible
Staphylococcus aureus
DNAse and MSA positive;
OR DNAse and MSA
discrepanta AND S. aureus
on VITEK 2
Cefoxitin susceptible on
disk diffusion testingb
Detection of
spa gene
Absence of mecA
Coagulase-negative
staphylococci
DNAse and MSA negative;
OR DNAse and MSA
discrepant AND no
agglutination using
Pastorex Staph Plus;
OR CoNS species on VITEK 2
Cefoxitin disk diffusion
testing resultb
Absence of
spa gene
Presence (resistant) or
absence (susceptible)
of mecA
DNAse Deoxyribonuclease, MSA Mannitol Salt Agar, CoNS Coagulase-negative staphylococcus
aPastorex Staph Plus-tested isolates exhibiting agglutination were all subjected to VITEK 2 confirmation. Isolates with no agglutination were considered coagulase-
negative staphylococci, or were subjected to VITEK 2 identification at the discretion of the clinical microbiologist
bCefoxitin category determined by clinical breakpoints outlined in the Clinical and Laboratory Standards Institute M100 document (2016)
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231 samples were included in the study (19.9, 95% CI 17.7–
22.4%) due to convenience sampling. Selected variables were
compared between the participants included in the study and
all patients for whom blood cultures were submitted showing
Gram positive cocci in clusters on Gram stain, between Janu-
ary and June 2016. No differences in age, gender or ward loca-
tion per organism type at blood culture sampling were noted,
with the exception of a larger proportion of coagulase-
negative staphylococci from patients admitted to surgical
wards (15.9% vs 9.2%, p 0.006) and high care units/ICU
(15.9% vs 8.3%, p 0.002) in the study population. Contribution
of the bottle types is outlined in Table 2.
Validation
A valid Xpert result was initially obtained from 225/231
bottles (97.4, 95% CI 94.5–98.8%). Of the remaining 6
assays, 2 (2.6, 95% CI 1.2–5.6%) were invalid (failure of
internal control) and were not repeated. Four were re-
sulted as “error” with signal loss after initial amplifica-
tion; two provided a valid result after repeat testing. The
conservative failure rate was 1.7% (95% CI 0.7–4.4%),
with 227 bottles yielding an interpretable result.
MSSA was present in 42 samples (18.5, 95% CI 14.0–
24.1%) and MRSA in 15 (6.6, 95% CI 4.1–10.6%). CoNS were
present as the sole isolate in 169 patients, and were part of
mixed cultures in an additional 4 cases. Three of these 4
mixed cultures contained MSSA together with CoNS, were
detected as MSSA by the Xpert, and were included as MSSA
in the analysis. The fourth culture contained Klebsiella pneu-
moniae (Gram negative bacilli missed on Gram stain) and a
CoNS; the Xpert correctly assessed the CoNS.
There was 100% concordance between the systems for
the identification of MSSA, MRSA and CoNS. The Xpert
assay had an overall sensitivity of 100% (57/57; 95% CI
93.7–100%), and specificity of 100% (170/170, 95% CI
97.8–100%). The positive and negative predictive values
of the assay were both 100% (95% CIs 93.7–100% and
97.8–100% respectively). Analysis by MSSA, MRSA and
CoNS is summarised in Supplementary Table 1.
We performed a subanalysis of mecA and methicillin
resistance in CoNS, for the 169 isolates in which cefoxi-
tin susceptibility on culture was known. The gene target,
mecA, was detected in 85 of 88 CoNS isolates that were
cefoxitin-resistant on culture (96.6%; 95% CI 90.5–
98.8%) giving a positive predictive value of 86.7% (95%
CI 78.6–92.1%). The specificity of detection of mecA in
CoNS on Xpert was 84.0% (95% CI 74.5–90.4%) with a
negative predictive value of 95.8% (95% CI 88.3–98.6%).
Potential impact of implementation
The median time between blood culture positivity and final result au-
thorisationwas 31.3h (interquartile range (IQR) 20.7–42.5h).
Of the 227 patients included, 50.7% (115/227, 95% CI
44.0–57.3%) were males. The median age of the adults
included was 43.0 years (IQR 31.0–58.0); the median age
of the paediatric population was 71.5 days (IQR 17.8–
325.0). Twenty-five adults (25/151, 16.6, 95% CI 11.2–
23.7%) and 10 children (10/76, 13.2, 95% CI 6.8–23.3%)
were admitted to an ICU at the time of blood culture
collection. Sepsis was CA in 51.1% (116/227, 95% CI
44.4–57.8%), HA in 38.3% (87/227, 95% CI 32.0–45.0%);
and unknown in the remaining 10.6% (24/227, 95% CI
7.0–15.5%). Only 1/11 with MRSA BSI reportedly had
CA onset of infection (9.1, 95% CI 0.5–42.9%).
Adequate history regarding source of sepsis was obtained
for 195 patients. Sixty-two patients (31.8, 95% CI 25.4–
38.9%) had an unclear source of sepsis. Respiratory tract in-
fection was the most commonly identified suspected source
overall (56/195, 28.7, 95% CI 22.6–35.7%) and in CA-
infection (33/101, 32.7, 95% CI 23.9–42.8%). For HA-
infection, 29 patients (36.3, 95% CI 26.0–47.8%) had no clear
source of sepsis; of those with known primary sources, the
major foci were the respiratory tract and skin or skin struc-
tures (both 18/80 patients, 22.5, 95% CI 14.2–33.5%).
Information on the suspected source of sepsis was ob-
tained in 46 patients with S. aureus BSI. The most com-
monly identified suspected source of sepsis (in isolation
or as part of two potential sources) was skin or skin
structure infection (n = 16, 34.8%), followed by suspected
respiratory tract infection (n = 11, 23.9%). Source was
undetermined at the time of clinician interview in 8 pa-
tients with S. aureus BSI (17.4%).
Characteristics of the included patients can be found
in Supplementary Table 2.
Impact on antibiotic administration
Adequate antibiotic history was obtained in 181 patients, in-
cluding 34 with MSSA and 11 with MRSA BSI. Three patients
were unclassified due to discordance between culture result,
clinical history and antibiotic therapy; these were excluded
from the analysis (additional notes in Supplementary Table 3).
Empiric antibiotic therapy choices for the remaining 178 pa-
tients (including one with significant CoNS BSI resulting from
a central line infection) are outlined in Fig. 1.
The antibiotic changes over time are summarised in Fig. 2
(whole cohort) and Table 3 (subgroup with S. aureus BSI).
The impact of the Xpert could be discerned by proxy if cul-
ture result availability approximated availability of the Gram
Table 2 BacT/Alert blood culture bottles included in the
diagnostic evaluation of Xpert MRSA/SA BC
Bottle Type n (%) 95% confidence interval
FA Plus 132 (57.1) 50.5–63.6
FN Plus 19 (8.2) 5.2–12.7
PF Plus 80 (34.6) 28.6–41.2
Total 231 –
Xpert Xpert MRSA/SA BC assay, FA Plus FAN Aerobic Plus, FN Plus FAN
Anaerobic Plus, PF Plus Paediatric FAN Plus
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stain result (i.e. final result available about an hour after
Gram stain availability, in place of the overnight incubation
required by reference methods). Analysis by organism cat-
egory (MRSA, MSSA or CoNS) can be found in Supplemen-
tary Table 4.
MRSA
Most patients with MRSA BSI did not receive an MRSA-
active agent until release of the final culture result (Table 3).
Cessation of an additional antimicrobial agent occurred in 7
patients on final culture result (63.6, 95% CI 31.6–87.6%);
this could have occurred at least 1 day sooner with Xpert.
MSSA
For the 34 patients who had MSSA BSI, notable aspects
of the antibiotic regimen include:
 Empiric cover: Empiric vancomycin was prescribed
unnecessarily in 3/34 (8.8, 95% CI 2.3–24.8%); this
could have been avoided if Xpert was used.
 In response to Gram stain availability: 2/34 (5.9, 95%
CI 1.0–21.1) received modifications to their
antibiotic regimens in response to Gram stain result
availability. In one case, vancomycin was started
when the Gram stain became available, for
suspected HA-sepsis. In the second, a non MSSA-
active beta-lactam agent (ampicillin) was changed to
an MSSA-active agent (cefotaxime).
 In response to final culture result availability:
Overall, there was a change in antibiotic therapy on
final result in 25 patients (73.5, 95% CI 55.4–86.5%).
These could have occurred at least 1 day earlier had
the Xpert assay been used.
○ De-escalation to a semisynthetic penicillin in
18/25 (72.0, 95% CI 50.4–87.1%)
○ Modification to a more effective agent in the
remaining 7/25 (28.0, 95% CI 12.9–49.6%)
CoNS
Antibiotics were stopped in 13/133 patients on re-
lease of the final result indicating CoNS (9.8, 95%
CI 5.5–16.5%).
Antimicrobial stewardship impact
Overall, 31/45 patients with S. aureus BSI and known
antibiotic history could have received more appropriate
antistaphylococcal therapy 1 day sooner, with adoption
of the Xpert assay (68.9, 95% CI 53.2–81.4%). Eleven of
the 45 patients (24.4, 95% CI 13.4–39.9%) were not re-
ceiving an agent with activity against their pathogen fol-
lowing Gram stain result availability (6 patients with
MRSA and 5 with MSSA BSI).
Days of therapy potentially saved
In the 178 patients with known antibiotic history, at
least 32 days of exposure to a broad spectrum beta-
lactam (beta-lactam-beta-lactamase inhibitor combin-
ation, extended-spectrum cephalosporin or carbapenem)
could have been spared with earlier knowledge of the
final result, equating to a reduction in broad spectrum
beta-lactam use in 18.0% of the patients in this study
(32/178, 95% CI 12.8–24.6%).
A further 5 days of vancomycin use could have been
avoided, and 17 days of antibiotic therapy could have been
spared for the other agents (Supplementary Table 5). This
equates to a reduction of 0.3 antibiotic days per patient
(95% CI, 0.2–0.4).
In total, at least 54 days of antibiotic therapy could
have been spared in the 178 patients with GPCC on
blood culture in this study.
Discussion
Evaluation
The Xpert MRSA/SA BC system reliably differentiated S.
aureus from CoNS. The assay showed a high sensitivity
and specificity, was easy to use and is potentially
Fig. 1 Empiric antibiotics in patients with GPCC on blood culture and adequate antibiotic history. MSSA: methicillin-sensitive Staphylococcus
aureus; GPCC: Gram positive cocci in clusters. aCeftriaxone/cefotaxime were included as MSSA-active beta-lactam agents when used empirically
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implementable in a South African setting, where Xpert
modules are widely available as part of the national
programme for diagnosis of tuberculosis.
Methicillin resistance was detected with 100% ac-
curacy in S. aureus; the small MRSA sample size pre-
cludes firm conclusions. Methicillin resistance in S.
aureus is chiefly mediated by mecA at present, al-
though mecC-mediated resistance has been reported
in 0.004% of human isolates [6]. The assay also per-
formed well for MSSA BSI, showing 100% concord-
ance with culture-based testing. The error rate of
1.7% is similar to previous reports [3, 7] and is ac-
ceptable. Although this assay has not been rigorously
tested for the detection of methicillin resistance in
CoNS to date, the negative predictive value of 95.8%
in this context may be useful in selected cases of po-
tentially significant CoNS bloodstream infection.
We recommend conventional culture to be per-
formed at least limitedly in parallel, for mixed cul-
tures, as a backup in case of an unsuccessful Xpert
result and for further antimicrobial susceptibility test-
ing or surveillance. Genotype-phenotype mismatch,
with the Xpert assay incorrectly reporting a suscep-
tible methicillin result due to insertions in the
SCCmec-orfX junction region, has been reported in 3
S. aureus isolates from the United States [8], and mis-
classification of S. aureus as CoNS in 2 isolates from
Australia [9]. Studies investigating the prevalence of
mutations that may affect the targets of this assay in
a South African setting are needed to define the role
of this assay more accurately.
Potential impact of implementation
To our knowledge, this is the largest study assessing the
potential impact of this assay to date. The median time
saving to final result with use of this assay was approxi-
mately 30 h if the Xpert assay was performed immediately
after microscopy, in line with previous estimates of a time
saving of 24–48 h [2, 10]. This crude estimate can be in-
fluenced by factors such as workflow. Antibiotic therapy
was optimised on availability of final result in 68.9% with
S. aureus BSI. This impact was most clearly demonstrated
in patients with MRSA BSI, where more than 50% re-
ceived anti-MRSA therapy only in response to the final
culture result. A more modest impact could be seen for
patients with MSSA BSI (approximately 21%); however, it
must be noted that this is a conservative estimate as all
beta-lactam agents were considered to have activity
against MSSA in this analysis, although they may not be
Fig. 2 Antibiotic progression at Gram stain availability and final culture result availability. CI: confidence interval. a Modification: change from an
ineffective to a more effective agent, or the addition of a semisynthetic penicillin (methicillin-susceptible S. aureus) or glycopeptide (methicillin-
resistant S. aureus); b De-escalation: change to a narrower-spectrum, targeted antistaphylococcal agent, or cessation of some or all antibiotics
Table 3 Antibiotic progression in patients with Staphylococcus aureus bloodstream infection with antibiotic history (n = 45)
Methicillin-sensitive S. aureus (n = 34) Methicillin-resistant S. aureus (n = 11)
Empiric
Choice
n (%) [95%
CI]
In response to
Gram result
n (%) [95% CI]
On culture
result
n (%) [95%
CI]
Empiric
choice
n (%) [95%
CI]
In response to
Gram result
n (%) [95% CI]
On culture
result
n (%) [95%
CI]
Patients receiving an agent with activity
against the organism isolateda
27 (79.4)
[61.6–90.7]
29 (85.3) [68.2–
94.5]
34 (100)
[87.4–100]
3 (27.3) [7.3–
60.7%]
5 (45.5) [18.1–75.4] 11 (100.0)
[67.9–100.0]
MRSA Methicillin-resistant Staphylococcus aureus, MSSA Methicillin-sensitive Staphylococcus aureus, CI Confidence interval
aEmpiric cover for MSSA included any agent with anti-MSSA activity, including ceftriaxone/cefotaxime for MSSA. Empiric cover for MRSA consisted of vancomycin
in our setting
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equally suitable for the treatment of MSSA BSI and some
are associated with a higher odds of death [11].
More rapid administration of appropriate therapy can
significantly impact mortality. In one study, the mean
mortality rate was 59% for patients with MRSA BSI who
were initially started on a semisynthetic penicillin, as op-
posed to 23–36% for patients initially started on vanco-
mycin [12]. The mean mortality rate was as low as 12%
in patients empirically placed on a semisynthetic penicil-
lin, who cultured MSSA [12]. Future studies should spe-
cifically assess the clinical impact of Xpert on more
appropriate S. aureus therapy.
We estimated a reduction in broad spectrum beta-
lactam antibiotic use in 18.0% of the cohort where anti-
biotic history was available, with 54 days of antibiotic
therapy saved. This translates to a modest reduction in
antibiotic days of therapy of 0.3 days per patient. When
combined with the benefits shown in optimising therapy
for S. aureus BSI infection, this may still be regarded as
advantageous, particularly when considered with the
consequences of unnecessary antibiotic prescription.
We initially expected this assay to be of most use in redu-
cing antibiotic therapy in patients with CoNS, as has been re-
ported previously [13], but this finding was not replicated. The
vast majority of CoNS bloodstream isolates were regarded as
being not clinically significant in this cohort, in keeping with
the high rate of blood culture contamination in our setting
[14]. Clinicians thus disregarded this “contaminated” result
and continued the empiric antibiotic regimen that had been
commenced based on the initial clinical assessment. Decisions
regarding antibiotics are also governed by other factors not
measured in this study, such as the clinical response to anti-
biotic therapy and additional test results. Although availability
of relevant rapid diagnostic tests such as the Xpert is a core
element to antimicrobial stewardship programmes in health-
care facilities in low-middle income countries [15], good qual-
ity microbiological sampling is also crucial and results in more
appropriate use of laboratory resources. Ongoing educational
interventions to optimise blood culture sampling (and reduce
blood culture contamination) is a relatively cost-effective and
easily implementable measure that can be instituted before
turning to more costly solutions, and it is important that this
remains a focus of antimicrobial stewardship programmes in
resource-limited settings.
The potential benefits described must be weighed
against the expense of the assay, including additional
labour, infrastructure and consumable costs. The total
cost of the test may be prohibitive in a resource-
constrained setting such as our own.
Limitations to this study include that the S. aureus BSI
rate was only 25.1% of all blood cultures with Gram posi-
tive cocci in clusters, and that methicillin resistance was
detected in 26.3% of all S. aureus-containing blood cul-
tures (similar to a contemporaneous study in our setting
(27.1%) [16]); this resulted in modest absolute numbers of
MSSA and MRSA BSI. This may confer a more moderate
impact of test performance than would be seen in higher
prevalence settings. CA-MRSA is also not common in our
setting currently [17]. Secondly, complete clinical records
were not available for all patients, prohibiting case-by-case
assessment of whether antibiotic changes occurred as a re-
sult of the microbiological results or the evolving clinical
picture. Furthermore, clinician recall bias may have influ-
enced these results. Thirdly, other patient comorbidities,
such as renal failure and severity of illness, may have con-
tributed to the choice of agents used and the decision to
modify antibiotic therapy; this could not be easily assessed.
Fourthly, we sampled a proportion of those eligible for in-
clusion; although we compared these populations for all
the key variables that would be available in a routine diag-
nostic laboratory setting (thereby limiting selection bias),
other variables, such as source of sepsis, were not taken
into account. Additionally, significant CoNS BSI may have
been underestimated in this study, as clinicians in our set-
ting infrequently adhere to recommendations for multiple
blood cultures to be submitted in the investigation of sep-
sis. Finally, most beta-lactam agents were considered to
have anti-MSSA activity for the purposes of this study,
which may result in an underestimate of the clinical bene-
fit of the assay for MSSA BSI.
Conclusion
The Xpert MRSA/SA BC assay performed well in differen-
tiating S. aureus from CoNS on positive blood cultures
with Gram positive cocci in clusters and in detecting
methicillin resistance in S. aureus, and the assay may be
an effective antimicrobial stewardship tool. Further studies
may need to be performed in areas with differing blood
culture contamination and MRSA rates. We demonstrated
potential benefit in reducing time to appropriate therapy
in the majority of patients with S. aureus bloodstream in-
fection. Antibiotic modification based on the clinical re-
sponse may have played a role in amplifying or
attenuating the benefit observed in this study. We showed
a modest reduction in antibiotics prescribed; studies lim-
ited to a more homogenous population may show a
greater benefit. Additional studies assessing potential im-
pact should focus on individual patient clinical status and
outcomes, and should take into account source control,
cost reduction in terms of antibiotic administration and
hospital stay, and comprehensive costing.
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